Want to see HK:6127 full AI Analyst Report?
6127 Stock Chart & Stats
HK$21.12
HK$0.01(0.12%)
At close: 4:00 PM EST
HK$21.12
HK$0.01(0.12%)
Day’s Range― - ―
52-Week RangeHK$15.13 - HK$29.98
Previous CloseN/A
Volume546.17K
Average Volume (3M)4.30M
Market Cap
HK$37.39B
Enterprise ValueHK$8.84K
Total Cash (Recent Filing)HK$4.23B
Total Debt (Recent Filing)HK$82.43M
Price to Earnings (P/E)35.0
Beta1.43
Next Earnings
Nov 04, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield0.5%
Share Statistics
EPS (TTM)1.33
Shares Outstanding118,995,210
10 Day Avg. Volume4,848,611
30 Day Avg. Volume4,303,293
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)1.65
Price to Sales (P/S)8.31
P/FCF Ratio45.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$23.00Price Target Upside8.90% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)1.27
Revenue Forecast (FY)HK$2.21B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetDebt-to-equity near zero across periods, including about 0.01 TTM, limits financing risk and preserves flexibility for laboratory investment or resilience. Steadily rising equity and improved TTM ROE indicate better returns without relying on leverage.
TTM Revenue Re-accelerationTTM revenue growth of 28.4% indicates a meaningful rebound after two annual declines, while strong current profitability improves internal funding capacity. If sustained, this recovery could support scale and strengthen the platform’s ability to serve outsourced development demand.
Diversified CRO Service ModelThe fee-for-service model serves external pharmaceutical and biotechnology customers with preclinical studies, technical services, and regulatory-enabling work. Project contracts plus ongoing arrangements give JOINN multiple ways to monetize its research platform as customers outsource development activities.
Bears Say
Inconsistent Revenue TrajectoryAnnual revenue declines in 2024 and 2025, despite the TTM rebound, show that demand conversion has not been consistently upward. This uneven trajectory makes it harder to underwrite a durable growth rate and increases dependence on continued recovery in coming quarters.
Profitability VolatilityLarge swings in profitability across annual periods reduce confidence that the unusually strong TTM margin profile can persist. Even with current improvement, the historical compression indicates that operating performance remains uneven and could make future earnings less predictable.
Weak Earnings-to-cash ConversionOperating cash flow covering only about half of net income, with free cash flow below reported earnings, indicates imperfect cash conversion. This can limit internally funded reinvestment and suggests working-capital or timing effects may affect the quality and durability of profits.
JOINN Laboratories (China) Co., Ltd. Class H News
6127 FAQ
What was JOINN Laboratories (China) Co., Ltd. Class H’s price range in the past 12 months?
JOINN Laboratories (China) Co., Ltd. Class H lowest stock price was HK$15.13 and its highest was HK$29.98 in the past 12 months.
What is JOINN Laboratories (China) Co., Ltd. Class H’s market cap?
JOINN Laboratories (China) Co., Ltd. Class H’s market cap is HK$37.39B.
When is JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date?
JOINN Laboratories (China) Co., Ltd. Class H’s upcoming earnings report date is Nov 04, 2026 which is in 36 days.
How were JOINN Laboratories (China) Co., Ltd. Class H’s earnings last quarter?
JOINN Laboratories (China) Co., Ltd. Class H released its earnings results on Aug 28, 2026. The company reported HK$0.793 earnings per share for the quarter, beating the consensus estimate of HK$0.556 by HK$0.237.
Is JOINN Laboratories (China) Co., Ltd. Class H overvalued?
According to Wall Street analysts JOINN Laboratories (China) Co., Ltd. Class H’s price is currently Undervalued.
Does JOINN Laboratories (China) Co., Ltd. Class H pay dividends?
JOINN Laboratories (China) Co., Ltd. Class H pays a Annually dividend of HK$0.138 which represents an annual dividend yield of 0.5%. See more information on JOINN Laboratories (China) Co., Ltd. Class H dividends here
What is JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate?
JOINN Laboratories (China) Co., Ltd. Class H’s EPS estimate is 0.04.
How many shares outstanding does JOINN Laboratories (China) Co., Ltd. Class H have?
JOINN Laboratories (China) Co., Ltd. Class H has 118,995,210 shares outstanding.
What happened to JOINN Laboratories (China) Co., Ltd. Class H’s price movement after its last earnings report?
JOINN Laboratories (China) Co., Ltd. Class H reported an EPS of HK$0.793 in its last earnings report, beating expectations of HK$0.556. Following the earnings report the stock price went down -2.014%.
Which hedge fund is a major shareholder of JOINN Laboratories (China) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6127
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
JOINN Laboratories (China) Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
HK$23.00 (8.90% Upside)
HK$23.00 (8.90% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.10%
12-Months-Change
Fundamentals
Return on Equity
0.50%
Trailing 12-Months
Asset Growth
20.57%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
JOINN Laboratories (China) Co., Ltd. Class H
Joinn Laboratories (China) Co., Ltd. is a global provider of essential preclinical and non-clinical research services, operating across the United States, mainland China, and various international markets. The company organizes its operations into three primary divisions: Non-Clinical Studies, Clinical Trial and Related Services, and Research Model Sales. The Non-Clinical Studies segment specializes in comprehensive drug safety assessments, pharmacokinetic and drug metabolism research, and pharmacology and efficacy investigations. Within its Clinical Trial and Related Services segment, the firm delivers clinical contract research organization (CRO) support, co-manages specialized Phase I clinical research facilities, and provides bioanalytical testing. The Research Model Sales division is responsible for the development, breeding, and distribution of diverse animal models for research purposes, encompassing non-human primates and rodents. Furthermore, Joinn Laboratories also extends its offerings to include investment management and cell-based assay (CBA) services. Established in 1995, the company is headquartered in Beijing, China.
6127 Stock 12 Month Forecast
Average Price Target
HK$23.00
▲(8.90% Upside)
Technical Analysis
Genscript Biotech
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―